Could the Neuropeptide Substance P Protect Motor Neurons in ALS?
Substance P levels are altered in the brain, spinal cord, and cerebrospinal fluid of ALS patients and animal models, with evidence suggesting it may contribute to selective motor neuron resistance.
Quick Facts
What This Study Found
Substance P is altered in ALS patients and may play a neuroprotective role by inhibiting excitotoxicity-induced motor neuron death, potentially contributing to the selective sparing of certain motor neuron populations.
Key Numbers
Worldwide obesity prevalence is increasing dramatically with significant economic burden.
How They Did This
Narrative review synthesizing clinical data on SP levels in ALS patients, preclinical studies of SP's neuroprotective effects, and mechanistic studies of SP's role in motor neuron excitability and survival.
Why This Research Matters
ALS has no cure and limited treatment options. Understanding why certain motor neurons resist degeneration could reveal new therapeutic targets, and substance P's potential neuroprotective role opens a novel avenue for drug development.
The Bigger Picture
The selective vulnerability of motor neurons in ALS is one of the disease's most puzzling features. If substance P contributes to protecting certain motor neuron populations, boosting SP signaling could potentially extend this protection to vulnerable neurons.
What This Study Doesn't Tell Us
Review article synthesizing observational and preclinical data; causal relationship between SP levels and motor neuron protection not definitively established; SP has multiple functions throughout the nervous system complicating therapeutic targeting; no clinical trials of SP-based ALS therapies reported.
Questions This Raises
- ?Could NK1R agonists slow motor neuron degeneration in ALS patients?
- ?Is substance P deficiency a cause or consequence of motor neuron loss?
- ?Can SP-based protection be enhanced in the most vulnerable motor neuron populations?
Trust & Context
- Key Stat:
- Selective sparing substance P may explain why certain motor neurons resist ALS degeneration
- Evidence Grade:
- Preliminary evidence from clinical observations and preclinical studies. The neuroprotective hypothesis is plausible but unproven in clinical settings.
- Study Age:
- Published in 2024, synthesizing current understanding of substance P in ALS pathophysiology.
- Original Title:
- Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease.
- Published In:
- Polish archives of internal medicine, 134(2) (2024)
- Database ID:
- RPEP-09384
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does substance P have to do with ALS?
Substance P is a neuropeptide that appears to be abnormally reduced in ALS patients' nervous systems. Research suggests it normally helps protect motor neurons from the toxic processes that kill them in ALS, and may explain why some motor neurons (like those controlling eye movement) are spared.
Could substance P become a treatment for ALS?
It's an early-stage idea, but the evidence that SP protects against excitotoxicity — a major motor neuron killer in ALS — makes it a promising therapeutic target worth investigating in future clinical trials.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09384APA
Tirandi, Amedeo; Montecucco, Fabrizio; Carbone, Federico; Liberale, Luca. (2024). Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease.. Polish archives of internal medicine, 134(2). https://doi.org/10.20452/pamw.16658
MLA
Tirandi, Amedeo, et al. "Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease.." Polish archives of internal medicine, 2024. https://doi.org/10.20452/pamw.16658
RethinkPeptides
RethinkPeptides Research Database. "Role of glucagon-like peptide-1 receptor agonists in the tre..." RPEP-09384. Retrieved from https://rethinkpeptides.com/research/tirandi-2024-role-of-glucagonlike-peptide1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.